Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study.
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin...
https://pubmed.ncbi.nlm.nih.gov/28511673/Actively Recruiting
Led by Maastricht University Medical Center · Updated on 2025-04-04
80
Participants Needed
8
Research Sites
26 weeks
Total Duration
Researchers are studying the use of oral hedgehog inhibitors, vismodegib and sonidegib, for treating locally advanced basal cell carcinoma laBCC, metastatic basal cell carcinoma mBCC, and basal cell nevus syndrome BCNS patients. This prospective registration study in the Netherlands aims to evaluate the effectiveness of these drugs and compare their outcomes, as no direct comparative studies have been performed yet. The study gathers detailed patient, tumor, and treatment data to better understand these therapies.
CONDITIONS
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
E
Emmy Cruts, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Maastricht University Medical Center
Lead Sponsor
Sun Pharmaceutical Industries Limited
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to approximately 3 years or until discontinuation of treatment
Participants take oral hedgehog inhibitors vismodegib or sonidegib daily or every other day as prescribed by their doctor. Effectiveness and adverse events are monitored during treatment.
Visits at baseline, after 1 month, and every 3 months during treatment; quality of life assessments every 6 months
Duration - 3 months after treatment discontinuation
After stopping treatment, participants are monitored for adverse events and quality of life continues to be assessed.
1 visit at 3 months post-treatment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Aleksandar Sekulic, Michael R Migden, Nicole Basset-Seguin...
https://pubmed.ncbi.nlm.nih.gov/28511673/Aleksandar Sekulic, Michael R Migden, Karl Lewis...
https://pubmed.ncbi.nlm.nih.gov/25981002/Pingxing Xie, Philippe Lefrançois
https://pubmed.ncbi.nlm.nih.gov/30003981/Karl Lewis, Reinhard Dummer, Aaron S Farberg...
https://pubmed.ncbi.nlm.nih.gov/34669179/R Dummer, P A Ascierto, N Basset-Seguin...
https://pubmed.ncbi.nlm.nih.gov/31990414/Brigitte Dréno, Rainer Kunstfeld, Axel Hauschild...
https://pubmed.ncbi.nlm.nih.gov/28188086/Alessia Villani, Claudia Costa, Gabriella Fabbrocini...
https://pubmed.ncbi.nlm.nih.gov/33301802/Aleksandar Sekulic, Michael R Migden, Anthony E Oro...
https://pubmed.ncbi.nlm.nih.gov/22670903/Babette J A Verkouteren, Marlies Wakkee, An K L Reyners...
https://pubmed.ncbi.nlm.nih.gov/33462360/Meydan Ben Ishai, Alon Tiosano, Eyal Fenig...
https://pubmed.ncbi.nlm.nih.gov/32407451/Maastricht University Medical Center
Lead Sponsor
Sun Pharmaceutical Industries Limited
Collaborating Sponsor